Coverage
-
September 12, 2011
Novelos Therapeutics Inc. argued Friday that a putative class of investors alleging the company misled them about the prospects of a developmental-stage cancer drug had failed for a third time to state a claim, and thus the complaint should be dismissed for good.
1 other articles on this case.
View all »